SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as an UBS upgrade sparked bullish sentiment, with the community eyeing a potential short squeeze and significant gains. Traders are closely watching NIO Day and ES8 deliveries, drawing comparisons to other EV manufacturers like Tesla. The stock is facing resistance, but many believe it has the potential to reach much higher prices.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending amid high volume and community excitement, fueled by speculation of upcoming government contracts. A recent congressional disclosure of stock purchases by a politician and Goldman Sachs increasing their holdings has further amplified the buzz. Traders are closely watching key resistance levels, anticipating a potential short squeeze and aiming for significant gains.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the company received UK regulatory approval for its acquisition of Oxford Ionics, potentially accelerating its technology roadmap; the community is actively discussing the deal's implications and future catalysts such as the Quantum World Congress. Bullish sentiment is fueled by analyst upgrades, increased price targets, and perceived momentum in the quantum computing sector, while bears question the valuation and long-term profitability.

Lazydays Holdings, Inc. retails recreational vehicles, motorcycles, jet skis and related accessories. The company operates recreation vehicle dealerships, generating revenue by providing RV owners a full spectrum of products: RV sales, RV services, financing and insurance products, RV parts and accessories, RV rentals, third-party protection plans, and RV camping. Lazydays Holdings was founded in 1976 and is headquartered in Tampa, FL.

Lazydays Holdings Inc

Lazydays Holdings ($GORV) is trending due to a recent acquisition announcement and a letter of intent with Campers Inn, including consideration for furniture and equipment. The community is actively discussing the potential impact of this acquisition, with some speculating about a pump and dump, while others are encouraged by the company's book value. Discussions also include the possibility of future offerings and price targets.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Turbo Energy (TURB) is trending due to a significant $53 million contract to deploy solar storage projects, sparking excitement about the company's growth potential in the energy sector. Community discussions revolve around the stock's volatile price action, potential short squeeze opportunities, and comparisons to other high-flying stocks. Some traders are also noting its low float, which may contribute to price swings.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to its low float and potential for a short squeeze, mirroring the recent movements of other low-float stocks. The community is actively discussing its high trading volume relative to its float, with some suggesting it could reach new highs. Several users are pointing to the company's fundamentals, such as cash position and lack of debt, as reasons for potential growth.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as the community discusses its potential inclusion in the S&P 500 and the possibility of acquiring TikTok. Bullish sentiment is fueled by analysts raising price targets and expansion into international markets, while some traders are eyeing a potential pullback from recent highs and expressing concerns about overvaluation and manipulation.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as community members highlight its strength within the defense sector and potential for further gains, with some eyeing triple-digit prices. A catalyst appears to be related to upcoming events and potential news, leading to discussions around its involvement in key defense programs. Investors are actively discussing its valuation, growth prospects, and potential contracts within the broader context of increasing defense spending.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards HPC/AI, drawing comparisons to other miners already in the space like $IREN and $CIFR. Community members are weighing the company's existing Bitcoin mining operations against opportunities in the AI sector, while also noting a high short interest and potential for a short squeeze. Some traders are monitoring borrowing fees and levels, while others discuss technical indicators and potential price movements related to broader market trends.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending amid discussions around recent executive stock sales, a completed acquisition, and revised financial guidance, leading to mixed sentiment. While some investors express frustration over the stock's volatile behavior and perceived mismanagement, others remain bullish, pointing to the company's long-term potential and strategic moves. Community talking points include potential catalysts, market manipulation, and the impact of institutional ownership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral acromegaly drug candidate, Palsonify (paltusotine), showing sustained biochemical control and symptom relief across two Phase 3 studies.At the ENDO 2025 conference, Crinetics shared new data from its ongoing PATHFNDR-1 and PATHFNDR-2 studies, showing that patients who switched from monthly injections to once-daily oral Palsonify were able to keep their insulin-like growth factor 1 (IGF-1) and growth hormone levels steady for nearly two years.&nbsp;Symptom scores, based on the acromegaly symptom diary (ASD), also remained stable. Palsonify was generally well tolerated.In PATHFNDR-2, which studied patients with uncontrolled acromegaly, Palsonify led to sustained reductions in IGF-1 and symptom flares through 84 weeks.&nbsp;Notably, patients who had previously been on placebo experienced meaningful improvements after switching to Palsonify in the open-label extension (OLE).A pooled analysis of symptom scores across both studies showed a significant decrease in day-to-day symptom flares for patients switching from injectables from over 30% of days on somatostatin receptor ligand (SRL) to just 6.2% during stable Palsonify dosing, regardless of baseline control or treatment history.CEO Scott Struthers said the data reinforce Palsonify’s potential as a once-daily, next-generation treatment for acromegaly.&nbsp;Crinetics is also advancing Palsonify in a Phase 3 trial for carcinoid syndrome in patients with neuroendocrine tumors, following promising Phase 2 results in flushing and bowel movement control.In March, the European Medicines Agency (EMA) validated Crinetics' marketing authorization application (MAA) for Palsonify as a long-term maintenance therapy for acromegaly.&nbsp;The EMA had previously granted the drug Orphan Drug Designation in February.&nbsp;On Stocktwits, retail sentiment for Crinetics was ‘bullish’ amid ‘high’ message volume.Crinetics’ stock has declined 38.1% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trumps-35-tariff-threat-ripples-through-walmart-s-bangladesh-supply-chain-report/ch8B1KwR5Np">Trump’s 35% Tariff Threat Ripples Through Walmart’s Bangladesh Supply Chain: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Crinetics Pharmaceuticals' (CRNX) Palsonify (paltusotine) showed sustained biochemical control and symptom relief across two Phase 3 studies. (Photo credit: Getty Images)

Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years. 

Equity

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Futures Drop On DOJ's Google Crackdown, China Plunge

Futures Drop On DOJ's Google Crackdown, China Plunge

 US equity futures are lower on news that the DOJ is considering a breakup of Alphabet's Google search engine, in what would be a...

Strong Future for Crinetics Pharmaceuticals: A Comprehensive Buy Rating Justification

Crinetics Pharmaceuticals (CRNX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan W...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals

Latest Ratings for CRNX
 DateFirmActionFromTo Nov 2021JMP SecuritiesInitiates Coverage OnMarket Outperform Nov 2021Evercore ISI GroupInitiates Coverage OnOutperform Nov 2021HC Wainwright...

17 Analysts Have This To Say About Crinetics Pharmaceuticals

Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake

Bloomberg / Contributor / Getty Images

 Key TakeawaysBillionaire Stanley Druckenmiller added more than three dozen new positions to his portfolio in the first quarter, including Apple, Reddit...

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRNX News

CRNX Crinetics Pharmaceuticals Inc